Many patients living with metastatic breast cancer (mBS) now have a new treatment option.
In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...
MLabs, and the Department of Pathology laboratories at Michigan Medicine, recognized leaders for advanced diagnostic testing, are now participating in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial.
MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions...
MLabs will be exhibiting at the USCAP 2018 Conference held in Vancouver, BC, Canada. You can visit MLabs booth #506 during the exhibit hours...